
    
      This is a Phase 2b, international, multicenter, open-label extension study for participants
      who successfully completed blinded study drug in Study 007. This extension study will
      evaluate the long-term administration of ataluren administered 3 times per day (TID) at
      morning, midday, and evening doses of 20, 20, and 40 milligrams/kilogram (mg/kg),
      respectively, in participants with nonsense mutation Duchenne/Becker muscular dystrophy
      (nmDBMD).
    
  